Obstetrics & Gynecology Email Alerts
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Obstetrics & Gynecology 2003;102:1344-1351
© 2003 by The American College of Obstetricians and Gynecologists
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Hsu, K.-F.
Right arrow Articles by Chou, C.-Y.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Hsu, K.-F.
Right arrow Articles by Chou, C.-Y.

ORIGINAL RESEARCH

Clinical Significance of Serum Human Papillomavirus DNA in Cervical Carcinoma

Keng-Fu Hsu, MD, Soon-Cen Huang, MD, Jenn-Ren Hsiao, MD, Ya-Min Cheng, MD, Saprina P. H. Wang and Cheng-Yang Chou, MD

From the Department of Obstetrics and Gynecology, Institute of Clinical Medicine, and Department of Otolaryngology, College of Medicine, National Cheng Kung University, Tainan, Taiwan.

Address reprint requests to: Cheng-Yang Chou, MD, Department of Obstetrics and Gynecology, College of Medicine, National Cheng Kung University, 138 Sheng Li Road, Tainan 704, Taiwan; E-mail: Chougyn{at}mail.ncku.edu.tw.

OBJECTIVE: To study the association between serum human papillomavirus (HPV) deoxyribonucleic acid (DNA) and clinicopathologic prognostic factors and the clinical usefulness of serum HPV DNA in early-stage cervical cancer.

METHODS: Deoxyribonucleic acids extracted from cervical tissues and sera of patients with stage IB or IIA cervical cancer and 40 controls including patients with cervical carcinoma in situ or benign disease were examined for HPV DNA with L1 consensus and types 16– and 18–specific E7 primers. Multivariable logistic regression was used to determine significant correlates of positive serum HPV DNA, and the receiver operating characteristic curve was applied in risk-factor assessment.

RESULTS: Human papillomavirus DNA was not detected in sera from patients with carcinoma in situ or benign disease. Among the 112 patients with cervical cancer, we detected 27 positive samples (24.1%) in serum. Positive HPV DNA in serum was significantly associated with lymphovascular invasion and deep stromal invasion with or without parametrial extension (P < .001 for both conditions), pelvic lymph nodal metastasis (P = .001), large tumor size, and elevated levels of serum squamous cell carcinoma antigen (P < .001 for both conditions). When serum HPV DNA was used to predict high-risk patients who require adjuvant therapy, a sensitivity of 45.2%, a specificity of 88.6%, a positive predictive value of 70.4%, and a negative predictive value of 72.9% were obtained.

CONCLUSION: The presence of serum HPV DNA in patients with early-stage cervical cancer was correlated with poor prognosis factors that warrant adjuvant therapy.






HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2003 by the American College of Obstetricians and Gynecologists.